Loading...
 

Volume 35, Issue 1, March 2024



Sign in to download the Issue in PDF format.

Back to the list
Mediterr J Rheumatol 2024;35(1):115-22
Article Links
Should All Patients Trial Subcutaneous Methotrexate Prior to Commencing Biologic Therapy? A Real World Study
Anem Mirza, Muhammad K. Nisar
Authors Information
Department of Rheumatology, Luton & Dunstable University Hospital NHSFT, Luton, United Kingdom

A Mirza, M Nisar
Keywords: methotrexate, rheumatoid arthritis, psoriatic arthritis, biologics
References
  1. Symmons D, Turner G, Webb R, Asten P, Barrett E, Lunt M, et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology (Oxford) 2002; 41(7)793-800.
  2. National Institute for Health and Care Excellence [Internet].  NICE Guideline NG100 Rheumatoid arthritis in adults: management. 2018, updated 2020 [cited 19.07.2021]. Available at: https://www.nice.org.uk/guidance/ng100.
  3. Puig L. Methotrexate: new therapeutic approaches. Actas Dermosifiliogr 2014;105(6):583-9.
  4. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol 2016;68(1):1-26.
  5. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73(3):492-509.
  6. Nikiphorou E, Negoescu A, Fitzpatrick JD, Goudie CT, Badcock A, Östör AJ, et al. Indispensable or intolerable? Methotrexate in patients with rheumatoid and psoriatic arthritis: a retrospective review of discontinuation rates from a large UK cohort. Clin Rheumatol 2014;33(5):609-14.
  7. Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford) 2000;39(1):28-33.
  8. Kotyla P, Batko B, Zuber Z, Almgren-Rachtan A, Chudek J, Kucharz EJ. Effectiveness of subcutaneously administered methotrexate in patients with rheumatoid arthritis. Adv Clin Exp Med 2019;28(9):1229-35.
  9. Hazlewood GS, Thorne JC, Pope JE, Lin D, Tin D, Boire G, et al. The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis. Ann Rheum Dis 2016;75(6):1003-8.
  10. Herman RA, Veng-Pedersen P, Hoffman J, Koehnke R, Furst DE. Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients. J Pharm Sci 1989;78(2):165-71.
  11. Lebbe C, Beyeler C, Gerber NJ, Reichen J. Intraindividual variability of the bioavailability of low dose methotrexate after oral administration in rheumatoid arthritis. Ann Rheum Dis 1994;53(7):475-7.
  12. Schiff MH, Jaffe JS, Freundlich B. Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration. Ann Rheum Dis 2014;73(8):1549-51.
  13. Hoekstra M, Haagsma C, Neef C, Proost J, Knuif A, van de Laar M. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol 2004;31(4):645-8.
  14. Osman A, Mulherin D. Is parenteral methotrexate worth trying? Ann Rheum Dis 2001;60(4):432.
  15. Bingham SJ, Buch MH, Lindsay S, Pollard A, White J, Emery P. Parenteral methotrexate should be given before biological therapy. Rheumatology (Oxford) 2003;42(8):1009-10.
  16. Braun J, Kästner P, Flaxenberg P, Währisch J, Hanke P, Demary W, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 2008;58(1):73-81.
  17. Rutkowska-Sak L, Rell-Bakalarska M, Lisowska B. Oral vs. subcutaneous low-dose methotrexate treatment in reducing gastrointestinal side effects. Reumatologia 2009;47(7):207-11.
  18. Pavy S, Constantin A, Pham T, Gossec L, Maillefert JF, Cantagrel A, et al. Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine 2006;73(4):388-95.
  19. Bello AE, Perkins EL, Jay R, Efthimiou P. Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis. Open Access Rheumatol 2017;9:67-79.
  20. Kavanaugh A. Psoriatic arthritis: treat-to-target. Clin Exp Rheumatol 2012;30(4 Suppl 73):S123-125.
  21. Aletaha D, Smolen JS. Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. J Rheumatol 2002;29(8):1631-8.
  22. Ferrara G, Mastrangelo G, Barone P, La Torre F, Martino S, Pappagallo G, et al. Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting. Pediatr Rheumatol Online J 2018;16(1):46.
  23. NICE Technology appraisal guidance [Internet]. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. 2016, [cited 19.07.2021]. https://www.nice.org.uk/guidance/ta375/chapter/1-Recommendations.
  24. Fitzpatrick R, Scott DG, Keary I. Cost-minimisation analysis of subcutaneous methotrexate versus biologic therapy for the treatment of patients with rheumatoid arthritis who have had an insufficient response or intolerance to oral methotrexate. Clin Rheumatol 2013;32(11):1605-12.
  25. Lee J, Pelkey R, Gubitosa J, Henrick MF, Ganz ML. Comparing Healthcare Costs Associated with Oral and Subcutaneous Methotrexate or Biologic Therapy for Rheumatoid Arthritis in the United States. Am Health Drug Benefits 2017;10(1):42-9.